# US 10,864,255 B2 · Lipid hydrolysis therapy for atherosclerosis and related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,255 B2
- Document ID: US10864255B2
- Status: Granted
- Kind: B2
- Application number: 15/430,815
- Filed: 2017-02-13
- Published: 2017-06-01
- Granted: 2020-12-15
- Earliest claimed: 2000-02-04
- Assignees: Children's Hospital Medical Center
- Applicants: Children's Hospital Medical Center
- Inventors: Gregory A. Grabowski; Hong Du
- Web page: https://patentgrep.com/patent/US10864255B2

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A23L 33/18: Peptides; Protein hydrolysates
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- C12Y 301/01013: Sterol esterase (3.1.1.13)
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/021: for the expression of a heterologous nucleic acid
- C12N 2799/04: in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

## Claims

### Claim 1

A sterile, aqueous solution consisting of
a) human lysosomal acid lipase (hLAL) protein;
b) human serum albumin;
c) one or more buffers; and
d) water.

### Claim 2 (depends on 1)

A sealed ampule containing the composition of claim 1.

### Claim 3 (depends on 1)

A sealed vial containing the composition of claim 1.